Factor H Level Assay

Dense Deposit Disease, C3 Glomerulonephritis and atypical Hemolytic Uremic Syndrome 
Complement Factor H (FH; MW: 155 kDa) is an important fluid-phase and cell-surface regulator of alternative pathway (AP) activity. Patients with FH mutations or FH autoantibodies may have reduced plasma FH levels and/or function, and are at-risk to develop atypical hemolytic uremic syndrome or C3 glomerulopathy.

Indications for screening 
Testing is appropriate for patients with DDD, C3GN and aHUS. 

MORL screening methodology 
Enzyme-linked immunosorbent assay (ELISA)

Turnaround time 
Turnaround time is ~2 weeks.

Sample Required 
1 ml frozen EDTA plasma (please see testing requisition for specimen handling).

Cost & CPT Codes

The Clinical Diagnostics Service of the Molecular Otolaryngology & Renal Research Laboratories is a CLIA-approved, Joint Commission-accredited diagnostic laboratory.